Valuation: AtaiBeckley

Market Cap 2.73B 2.47B 2.28B 2.06B 3.88B 257B 4.02B 27.45B 10.88B 137B 10.23B 10.01B 436B P/E 2024
-1.43x
P/E 2025 -1.4x
Enterprise Value 2.47B 2.24B 2.07B 1.87B 3.53B 233B 3.65B 24.91B 9.88B 125B 9.29B 9.09B 396B EV / Sales 2024
609,588,266x
EV / Sales 2025 301,804,774x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day+0.82%
3 months+1.24%
6 months+81.93%
Current year+79.71%
Current year 3.26
Extreme 3.265
7.45
1 year 3.26
Extreme 3.265
7.45
3 years 1.02
Extreme 1.025
7.45
5 years 1.02
Extreme 1.025
13.32
10 years 1.02
Extreme 1.025
22.91
Date Insider Type Main position Quantity % Market Cap. Importance
11/09/26 Issuer sale

Chief Executive Officer

-10,179,823 2.7449%
11/09/26 Issuer sale

Director

-741,089 0.1998%
11/09/26 Issuer sale

Director

-430,968 0.1162%

Financials

2024 2025
Net sales 0.31 0.28 0.26 0.23 0.44 29.04 0.45 3.1 1.23 15.51 1.16 1.13 49.24 4.09 3.71 3.43 3.09 5.83 385.55 6.03 41.17 16.33 205.95 15.34 15.02 653.75
Net income -149M -135M -125M -113M -213M -14.07B -220M -1.5B -596M -7.52B -560M -548M -23.86B -660M -598M -553M -499M -941M -62.23B -974M -6.65B -2.64B -33.24B -2.48B -2.42B -106B
Net Debt -35.42M -32.1M -29.69M -26.79M -50.49M -3.34B -52.26M -357M -141M -1.78B -133M -130M -5.66B -251M -228M -211M -190M -358M -23.71B -371M -2.53B -1B -12.67B -944M -924M -40.2B
Projected Income Statement - Annual - AtaiBeckley
Logo AtaiBeckley
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
Employees
99
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - AtaiBeckley
  1. Stock Market
  2. Stocks
  3. ATAI Stock